- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2005-000808-14 | Sponsor Protocol Number: AD-CT-01/05 | Start Date: 2005-05-24 | ||||||
Sponsor Name: Ambria Dermatology | ||||||||
Full Title: A randomized, double-blind, parallell-group, controlled study of topical pentane-1,5-diol hydrogel in patients with impetigo | ||||||||
Medical condition: Impetigo | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: SE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005282-37 | Sponsor Protocol Number: IDT.LM.LEV.22004-LEMDE | Start Date: 2005-05-24 | ||||||
Sponsor Name: QUIMICA FARMACEUTICA BAYER, S.A. | ||||||||
Full Title: Double-blind, cross-over, placebo-controlled pilot study to characterize the profile of those patients with traumatic spinal cord injury diagnosed by electrophysiological, urodynamic and clinical (... | ||||||||
Medical condition: Erectile dysfunction (ED) | ||||||||
|
||||||||
Population Age: Adults | Gender: Male | |||||||
Trial protocol: ES (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-005184-15 | Sponsor Protocol Number: 05_ENDO_46 | Start Date: 2005-05-24 | ||||||
Sponsor Name: Christie Hospital NHS Trust | ||||||||
Full Title: Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism | ||||||||
Medical condition: Central (secondary/tertiary) hypothyroidism (subclinical) | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2005-000380-26 | Sponsor Protocol Number: CERTES02 (Ce-PoP-RAD001A2419) | Start Date: 2005-05-24 | |||||||||||
Sponsor Name: Novartis Farmacéutica S.A. | |||||||||||||
Full Title: A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3... | |||||||||||||
Medical condition: Renal Transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000807-33 | Sponsor Protocol Number: EFC5823 | Start Date: 2005-05-24 | |||||||||||
Sponsor Name: sanofi-aventis recherche & développement | |||||||||||||
Full Title: Randomized, double-blind, two -arms placebo-controlled, parallel-group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients. | |||||||||||||
Medical condition: Abdominally obese patients with atherogenic dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001378-29 | Sponsor Protocol Number: RAE02 | Start Date: 2005-05-23 | ||||||
Sponsor Name: Bradford Teaching Hospitals NHS Foundation Trust | ||||||||
Full Title: A double blinded randomised controlled trial of injection of botulinum toxin versus normal saline into the puborectalis muscle in patients with pelvic floor dyssynergia. | ||||||||
Medical condition: Obstructed defeacation | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004670-88 | Sponsor Protocol Number: 4975-2-007-2 | Start Date: 2005-05-23 | |||||||||||
Sponsor Name: AlgoRx Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects after Inguinal Hernia Repair | |||||||||||||
Medical condition: Inguinal Hernia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000867-24 | Sponsor Protocol Number: ALFR-HC-04 | Start Date: 2005-05-23 | ||||||
Sponsor Name: Human Genome Sciences, Inc. | ||||||||
Full Title: A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION... | ||||||||
Medical condition: Hepatitis type C chronic | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) CZ (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-002676-41 | Sponsor Protocol Number: 100388,103494,104105,104106 | Start Date: 2005-05-23 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ... | ||||||||||||||||||||||||||||
Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001774-27 | Sponsor Protocol Number: AISSM03 | Start Date: 2005-05-23 | |||||||||||
Sponsor Name: AISSM ONLUS | |||||||||||||
Full Title: CAMPATH-1H AS IMMUNOSUPPRESSIVE AGENT IN MDS PATIENTS MULTICENTRIC PILOT STUDY | |||||||||||||
Medical condition: In this study we want to assess the potential of CAMPATH-1H as an immunosuppressive agent in a series of selected MDS patients, because T lymphocytes are thought to play an important role in the ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |